background: the luteal phase defect is a common event following the ovarian stimulation. the aim of the present study was to evaluate the use of human chorionic gonadotropine (hcg) and progesterone hormones to improve the luteal phase defect. materials and methods: 60 mice were superovulated routinely with human menopausal gonadotropin (hmg) (7.5u) and hcg (10u). the mice were mated and divided...

OBJECTIVE To evaluate the impact of two different luteal phase support protocols on gene expression of extracellular matrix (ECM) proteins and adhesion molecules in the human endometrium. DESIGN Eighty-four ECM protein and adhesion molecule genes were analyzed using array-based reverse-transcription polymerase chain reaction. SETTING Academic hospital. PATIENT(S) Nine oocyte donors. INT...

background: the aim of this study, we have compared the advantages of oral dydrogestrone with vaginal progesterone (cyclogest) for luteal support in intrauterine insemination (iui) cycles. progesterone supplementation is the first line treatment when luteal phase deficiency (lpd) can reasonably be assumed. objective: this study was conduct to compare the effect of oral dydrogestrone with vagina...

Gonadotrophin-releasing hormone agonists (GnRHa) are widely used in in-vitro fertilization (IVF) for the prevention of a premature rise in luteinizing hormone (LH) concentrations. However, the administration of GnRHa during the follicular phase may also impair subsequent luteal function due to retarded recovery of pituitary gonadotrophin secretion. Therefore, luteal supplementation is generally...

background: there is no doubt that luteal phase support is essential to enhance the reproductive outcome in ivf cycles. in addition to progesterone and human chorionic gonadotropin, several studies have described gnrh agonists as luteal phase support to improve implantation rate, pregnancy rate and live birth rate, whereas other studies showed dissimilar conclusions. all of these studies have b...

The first report of the combined use of pituitary suppression and ovarian hyperstimulation in invitro fertilization (IVF) and embryo transfer programmes was published in 1984 (1). Since then, the advantages of gonadotrophin hormonereleasing hormone analogues (GnRHa) have been well documented; the cancellation rate has been decreased through the prevention of premature luteinizing hormone (LH) s...